2014 ACR/ARHP Annual Meeting

November 14-19, 2014. Boston, MA.

View by Title View Sessions

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 1554

Early and Sustained Modified Psarc Response in Psoriatic Arthritis Patients Treated with Ustekinumab: Results from 2 Phase 3 Studies
Abstract Number: 1335

Early Birds Versus Night Owls: Morning/Evening Preference and Its Association with Sleep Problems, Fatigue, and Emotional Well-Being Among RA Patients
Abstract Number: 1688

Early Detection of Left Ventricular Morphological, Functional Abnormalities and Myocardial Characteristics in Systemic Sclerosis without Cardiac Symptoms Using Cardiac Magnetic Resonance Imaging: A Preliminary Report
Abstract Number: 250

Early Gout Pain Response at 28 Hours Predicts Response at 5 Days on Both Patient Pain and Physician Global Assessment
Abstract Number: 796

Early Halo Sign Features on Ultrasound Examination of Treated Patients with Giant Cell Arteritis
Abstract Number: 723

Early Mortality in Australian, Canadian and Spanish Scleroderma Patients: Rationale for Establishing a Multi-National Inception Cohort of Patients with Systemic Sclerosis
Abstract Number: 1891

Early MRI Endpoints Provide a Valid Measure of Structural Damage While Reducing Study Duration and Participant Numbers in Rheumatoid Arthritis Clinical Trials
Abstract Number: 2903

Early Outcomes in Pediatric Antineutrophil Cytoplasmic Antibody (ANCA) Associated Vasculitis (AAV)
Abstract Number: 2499

Early Response Indicator early Predicts Clinical Response to Certolizumab in Rheumatoid Arthritis Patients
Abstract Number: 2503

Early Response to Full-Dose Etanercept-Plus-Methotrexate Induction Therapy Predicts Sustained Remission with Reduced-Dose Combination Therapy in Early Rheumatoid Arthritis Patients
Abstract Number: 2349

Early Sympathectomy Inhibits Egress of Lymphocytes in Control and Arthritic Animals and Ameliorates Arthritic Disease
Abstract Number: 2407

Early Treatment in Rheumatoid Arthritis and Its Effect on Patient Outcomes
Abstract Number: 1929

Echocardiographic Phenomics for Novel Classification of Cardiac Involvement in Systemic Sclerosis
Abstract Number: 1544

Economic and Comorbidity Burden Among Moderate-to-Severe Psoriasis Patients Comorbid with Psoriatic Arthritis
Abstract Number: 1595

Economic Evaluation of Sequencing Strategies in the Treatment of Psoriatic Arthritis in the United States

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].